Caring for Patients with Severe AsthmaEvolving Best Practices to Optimize Outcomes
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised,double-blind, placebo-controlled, phase 2b trial.
Brightling CE, et al. Lancet Respir Med. 2015;3(9):692-701.
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, et al. Lancet Respir Med. 2015;3(5):355-366.
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
D’Amato G, et al. Ther Clin Risk Manag. 2007;3(4):613-619.
Darveaux J, Busse WW. J Allergy Clin Immunol Pract. 2015;3(2):152-161.
Haldar P, et al. Am J Respir Crit Care Med. 2008;178:218-224.
Gandhi NA, et al. Nat Rev Drug Discov. 2016;15(1):35-50
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM, et al. Lancet. 2016;388(10056):2128-2141.
Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.
Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.
Wechsler ME. Am J Med. 2014;127(11):1049-1059.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, et al. Lancet. 2016;388(10039):31-44
Clinical Insights Into Severe Asthma Pathophysiology
Michael Wechsler, MD, MMSc
Caring for Patients with Severe Asthma Teaser
Eugene R. Bleecker, MD; Sidney S. Braman, MD, FCCP; Richard J. Martin, MD
Severe Asthma and the Primary Care Provider Teaser
Michael E. Wechsler, MD, MMSc; Barbara P. Yawn, MD, MSc, FAAFP
Evolving Best Practices to Optimize Outcomes
Improving Patient Outcomes via Coordinated Multidisciplinary Care
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Consensus and Controversies on the Road to Precision Medicine
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making